Archives
FOXM1–ERα ceRNA Networks in Female Lung Adenocarcinoma: Insi
2026-07-17
FOXM1–ERα ceRNA Networks in Female Lung Adenocarcinoma: Mechanistic Insights and Research Tools
Study Background and Research Question
Female lung adenocarcinoma (LUAD) remains a leading contributor to cancer morbidity and mortality, representing nearly 40% of malignant lung tumors and disproportionately affecting women. Despite advances in targeted therapies, overall survival rates remain low—approximately 16%, highlighting the urgent need for mechanistic clarity and new biomarkers. The transcription factor FOXM1 has been implicated in oncogenesis across several cancer types, yet its role in LUAD, particularly among female patients, and its interaction with estrogen receptor signaling axes were previously uncharacterized. The reference study (Zhang et al., 2023) specifically addresses the molecular interdependence of FOXM1, noncoding RNAs, and estrogen receptor 1 (ERα) in LUAD pathogenesis and therapeutic responsiveness.Key Innovation from the Reference Study
The primary innovation of the Zhang et al. study lies in the establishment and cellular validation of a ceRNA network involving DGCR-5, has-miR-204-5p, FOXM1, and estrogen receptor 1 (ERα) as pivotal regulators of female LUAD. By leveraging integrated transcriptomic datasets, bioinformatic predictions, and cellular assays, the authors delineate how these molecular nodes interact to modulate both tumor progression and immunotherapy sensitivity. Notably, the research uncovers a direct physical and regulatory interaction between FOXM1 and ERα, positioning this axis as a mechanistic bridge between hormone signaling and oncogenic transcriptional control.Methods and Experimental Design Insights
The study's robust multi-omics methodology underpins its key findings:- Comprehensive data mining was performed using GDC TCGA and GEO datasets to identify differential gene expression patterns in LUAD versus normal tissues.
- Gene Set Enrichment Analysis (GSEA) elucidated the functional context of candidate biomarkers, with a focus on estrogen receptor signaling and immune cell infiltration.
- Survival and clinical correlation analyses established prognostic relevance, correlating FOXM1 and ERα expression with clinical outcomes.
- Bioinformatic tools (miRDB, miRTarBase, TargetScan) were applied to predict miRNA and lncRNA interactions, forming the basis for ceRNA network construction using Cytoscape.
- In vitro validation included FOXM1 knockdown in LUAD cell lines, with subsequent assays for cell proliferation, apoptosis, and direct molecular interactions between FOXM1 and ERα.
- Tumor mutational burden (TMB) and immune infiltration were assessed to link molecular profiles with predicted immunotherapy response.
Core Findings and Why They Matter
The study reports several key discoveries:- FOXM1 is overexpressed in female LUAD samples compared to normal tissue, with elevated levels correlating with worse prognosis and enhanced tumor proliferation (reference study).
- Knockdown of FOXM1 significantly impairs LUAD cell growth and increases apoptosis, underscoring its functional role as an oncogenic driver.
- A novel ceRNA network—DGCR-5 (lncRNA), has-miR-204-5p (miRNA), FOXM1, and ERα—was constructed and validated. The authors show that has-miR-204-5p directly targets FOXM1, but not DGCR-5, and that FOXM1 physically interacts with ERα.
- ERα is integral to this network, suggesting direct crosstalk between estrogen receptor alpha signaling and FOXM1-driven oncogenesis.
- Immunological analyses reveal that lower FOXM1 expression is associated with greater sensitivity to immunotherapeutics, including anti-PD1 and anti-CTLA4 agents. This finding links transcriptional regulation to tumor immune microenvironment and potential treatment outcomes.
Comparison with Existing Internal Articles
Recent internal literature highlights the strategic utility of selective ERα agonists, such as PPT (Propyl Pyrazole Triol), in dissecting estrogen receptor pathways in cancer models. For example, the article "PPT (Propyl Pyrazole Triol): Precision ERα Agonism for Translational Research" integrates findings from the FOXM1–ERα axis and discusses PPT’s role in enabling targeted activation of ERα for pathway dissection and biomarker validation. Similarly, "PPT (Propyl Pyrazole Triol): Precision Tools for ERα Signaling" provides protocol-centric guidance that aligns with the experimental design adopted in the reference study. These resources collectively underscore the translational potential of using subtype-selective ERα agonists to map transcriptional networks and validate candidate biomarkers in both breast and lung cancer contexts.Limitations and Transferability
While the study by Zhang et al. offers robust molecular and functional validation, several caveats should be noted:- The ceRNA network was constructed and validated primarily using female LUAD datasets and cell models; applicability to male LUAD or other histological subtypes remains to be established.
- In vitro experiments, while essential for mechanistic confirmation, may not fully recapitulate tumor microenvironment complexity found in vivo.
- The direct regulatory role of ERα within the ceRNA network requires further investigation, particularly in the context of hormonal modulation or pharmacological agonism.
- Translational and clinical validation, including patient-derived xenografts or prospective cohort analyses, would strengthen the prognostic and therapeutic relevance of the identified network.
Protocol Parameters
- FOXM1 knockdown: Utilize siRNA or shRNA transfection in LUAD cell lines; confirm knockdown efficiency via qPCR and Western blot at 48–72 hours post-transfection.
- ceRNA network validation: Perform luciferase reporter assays to confirm miRNA-target interactions (e.g., has-miR-204-5p targeting FOXM1 3' UTR).
- ERα activation assays: Employ selective ERα agonists in estrogen receptor-positive cell lines to dissect downstream gene expression changes, monitoring both FOXM1 and immune-related transcripts.